厄贝沙坦与沙库巴曲缬沙坦治疗老年慢性心力衰竭的效果分析  

Analysis of the Therapeutic Effects of Irbesartan and Sacubitril/Valsartan in Elderly Patients with Chronic Heart Failure

作　　者：任彦青 董平 Ren Yanqing;Dong Ping(Department of Cardiology,Beijing HuiMin Hospital,Beijing 100054,China)

机构地区：[1]北京市回民医院心血管内科,北京100054

出　　处：《中外医药研究》2025年第8期63-65,共3页JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH

摘　　要：目的:分析厄贝沙坦与沙库巴曲缬沙坦治疗老年慢性心力衰竭的效果。方法:选取2021年6月—2024年7月北京市回民医院收治的120例老年慢性心力衰竭患者,按照随机数字表法分为对照组和试验组,各60例。两组均接受常规治疗,对照组在常规治疗基础上接受厄贝沙坦治疗,试验组在常规治疗基础上接受沙库巴曲缬沙坦治疗。比较两组心功能、心肌损伤标志物相关指标、临床疗效及不良反应发生率。结果:治疗后,两组左心室射血分数升高,左心室收缩末期直径、左心室舒张末期直径降低,试验组优于对照组(P<0.05);治疗后,两组同型半胱氨酸、N末端脑钠肽前体、白细胞介素-6、细胞间黏附分子-1水平降低,试验组低于对照组(P<0.05);试验组治疗总有效率高于对照组(P=0.010);试验组不良反应发生率低于对照组(P=0.030)。结论:沙库巴曲缬沙坦治疗老年慢性心力衰竭的效果优于厄贝沙坦,可改善患者心功能、减轻心肌损伤、降低不良反应发生率。Objective:To analyze the therapeutic effects of irbesartan and sacubitril/valsartan in elderly patients with chronic heart failure.Methods:A total of 120 elderly patients with chronic heart failure admitted to Beijing HuiMin Hospital from June 2021 to July 2024 were selected and divided into a control group and a test group using the random number table method,with 60 cases in each group.Both groups received conventional treatment.The control group was additionally treated with irbesartan,while the test group was treated with sacubitril/valsartan.Cardiac function,myocardial injury biomarkers,clinical efficacy,and the incidence of adverse reactions were compared between the two groups.Results:After treatment,both groups showed an increase in left ventricular ejection fraction and decreases in left ventricular end-systolic diameter and left ventricular end-diastolic diameter,with the test group outperforming the control group(P<0.05).Levels of homocysteine,N-terminal pro-B-type natriuretic peptide,interleukin-6,and intercellular adhesion molecule-1 decreased in both groups,with the test group exhibiting lower levels than the control group(P<0.05).The total effective rate of treatment in the test group was higher than that in the control group(P=0.010).The incidence of adverse reactions in the test group was lower than that in the control group(P=0.030).Conclusion:Sacubitril/valsartan is superior to irbesartan in treating elderly patients with chronic heart failure,improving cardiac function,alleviating myocardial injury,and reducing the incidence of adverse reactions.

关 键 词：慢性心力衰竭 老年 厄贝沙坦 沙库巴曲缬沙坦 

分 类 号：R541.6[医药卫生—心血管疾病]